Heron Therapeutics, Inc. (NASDAQ:HRTX) to Post FY2028 Earnings of $0.54 Per Share, Capital One Financial Forecasts

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Research analysts at Capital One Financial lifted their FY2028 EPS estimates for Heron Therapeutics in a research note issued on Tuesday, July 2nd. Capital One Financial analyst T. Chiang now anticipates that the biotechnology company will post earnings of $0.54 per share for the year, up from their previous forecast of $0.47. Capital One Financial has a “Overweight” rating and a $6.00 price objective on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.10) per share.

Several other research analysts also recently commented on HRTX. Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research report on Thursday, May 16th. Rodman & Renshaw started coverage on shares of Heron Therapeutics in a report on Thursday, June 13th. They set a “buy” rating and a $7.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $6.00.

Heron Therapeutics Price Performance

Shares of HRTX opened at $2.77 on Thursday. Heron Therapeutics has a one year low of $0.50 and a one year high of $3.93. The company has a market cap of $417.31 million, a P/E ratio of -4.54 and a beta of 1.80. The firm has a 50 day simple moving average of $3.20 and a two-hundred day simple moving average of $2.72.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.06. The firm had revenue of $34.67 million for the quarter, compared to analyst estimates of $32.50 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its holdings in shares of Heron Therapeutics by 15.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 29,922 shares of the biotechnology company’s stock worth $83,000 after buying an additional 3,991 shares in the last quarter. Victory Capital Management Inc. grew its stake in shares of Heron Therapeutics by 30.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 4,617 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Heron Therapeutics by 3.1% in the first quarter. Commonwealth Equity Services LLC now owns 338,526 shares of the biotechnology company’s stock worth $938,000 after purchasing an additional 10,122 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Heron Therapeutics in the first quarter worth $30,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Heron Therapeutics in the first quarter worth $32,000. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.